Abstract

Parkinson’s disease (PD) is histologically described by the deposition of α-synuclein, whose accumulation in Lewy bodies causes dopaminergic neuronal death. Although most of PD cases are sporadic, point mutations of the gene encoding the α-synuclein protein cause inherited forms of PD. There are currently six known point mutations that result in familial PD. Oxidative stress and neuroinflammation have also been described as early events associated with dopaminergic neuronal degeneration in PD. Though it is known that microglia are activated by wild-type α-synuclein, little is known about its mutated forms and the signaling cascades responsible for this microglial activation. The present study was designed to investigate consequences of wild-type and mutant α-synuclein (A53T, A30P and E46K) exposure on microglial reactivity. Interestingly, we described that α-synuclein-induced microglial reactivity appeared to be peptide-dependent. Indeed, the A53T protein activated more strongly microglia than the wild-type α-synuclein and other mutants. This A53T-induced microglial reactivity mechanism was found to depend on phosphorylation mechanisms mediated by MAPKs and on successive NFkB/AP-1/Nrf2 pathways activation. These results suggest that the microgliosis intensity during PD might depend on the type of α-synuclein protein implicated. Indeed, mutated forms are more potent microglial stimulators than wild-type α-synuclein. Based on these data, anti-inflammatory and antioxidant therapeutic strategies may be valid in order to reduce microgliosis but also to subsequently slow down PD progression, especially in familial cases.

Highlights

  • Parkinson’s disease (PD) is one of the most common neurodegenerative diseases

  • Microglial cultures were exposed to the wild-type α-synuclein protein (WT, αsyn) as well as to three α-synuclein mutants (A53T, A30P and E46K)

  • Compared to wild-type α-syn protein (WT) and E46K preparations, which had equivalent amounts of dimers, the proportion of dimers was strongly lower in A30P (3-fold) and to a lesser extent in at position 53 of the α-syn protein (A53T) preparation (2-fold)

Read more

Summary

Introduction

Parkinson’s disease (PD) is one of the most common neurodegenerative diseases. This agerelated disorder is clinically characterized by several motor symptoms such as bradykinesia, resting tremor and muscular rigidity, and by non-motor symptoms as depression, gastrointestinal features and dementia [1,2]. PD is histologically described by the deposition of a physiological protein present in the brain, α-synuclein (α-syn).

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.